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was developed in UK English (Speight and Bradley; 2001) and most recently updated 
in 2008 in consultation with UK diabetologists, a diabetes specialist nurse (DSN), a 
dietician, and a podiatrist. A conceptual deﬁnition of each item was provided by the 
developer, forward translations were produced in Germany and Spain. Results of the 
ﬁrst translations and questions were discussed with the developer and a diabetologist, 
DSN, dietician and the translation team in each country. The initial UK version was 
revised. The German and Spanish versions were back translated into UK English and 
tested for acceptability and comprehension during cognitive debrieﬁng interviews with 
eight people with diabetes in each country, before ﬁnal language versions were estab-
lished. RESULTS: First results obtained after the forward translation and discussion 
in Spain and Germany showed that diabetes management differs somewhat across 
countries and differences in dietary habits and alcohol use necessitated some adapta-
tion to the questions. The establishment of a harmonized questionnaire required some 
rewording of items and reordering. Challenges encountered, including those concern-
ing diet and alcohol, and how these were dealt with during all steps of the process 
will be described in the presentation. CONCLUSIONS: An internationally acceptable 
version of the ADKnowl was developed following a rigorous methodology to facilitate 
international comparison and pooling of data. This project demonstrates the impor-
tance of assessing the suitability of the item content of a knowledge measure to the 
clinical and cultural context of the target countries.
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OBJECTIVES: To compare the impact of starting either insulin glargine once-daily 
or insulin detemir twice-daily on multiple dimensions of QOL in patients with type 
2 diabetes inadequately controlled on OGLDs. METHODS: This study was part of 
a 24-week, multinational, randomised trial in which 964 insulin-naïve patients, 
aged 40–75 years, with inadequately controlled type 2 diabetes (HbA1c 7.0–10.5%) 
were randomised to glargine once-daily or detemir twice-daily. For both insulins the 
dose was titrated every 2 days by 2 U to obtain fasting plasma glucose 5.6 mmol/l. 
For detemir, there also was a pre-dinner target 5.6 mmol/l. QOL and TS were 
assessed using: type 2 Diabetes Symptom Checklist revised (DSC-r), World Health 
Organization-5 well-being index (WHO-5), Hypoglycaemia Fear Survey (HFS) and 
Diabetes Treatment Satisfaction Questionnaire (DTSQ). Higher scores indicate greater 
symptom distress, well-being, worries about hypoglycaemia and TS, respectively. 
Data were analysed using ANCOVA. RESULTS: HbA1c reductions and overall 
hypoglycaemia were comparable between glargine and detemir (mean o SD change in 
HbA1c: 1.46 o 1.09 and 1.54 o 1.11%, respectively [P  0.149]). Total diabetes-
related symptom distress (DSC-r) decreased in both treatment groups. There were 
no signiﬁcant differences between groups, except for the neuropathic pain subscale 
(P  0.027 in favour of glargine). Well-being (WHO-5) increased equally in both 
groups (6.13 o 21.47 for glargine and 7.54 o 19.06 for detemir on scale 0–100, P 
 0.742). There was no signiﬁcant difference between treatments for the HFS (P  
0.441). TS (DTSQ) improved for both treatment groups, but signiﬁcantly more for 
glargine than for detemir: Mean o SD increase in total satisfaction score (scale 0–36): 
5.1 o 8.6 for glargine and 4.1 o 8.8 for detemir (P  0.001). CONCLUSIONS: Initiat-
ing glargine once-daily or detemir twice-daily in patients with type 2 diabetes failing 
OGLDs resulted in similarly improved glycaemic control, associated with an overall 
positive effect on diabetes symptom distress and emotional well-being. TS improved 
with both insulins, however, improvement was signiﬁcantly greater with glargine 
than detemir.
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OBJECTIVES: This study aims to estimate and compare quality of life and productiv-
ity loss among three chronic and prevalent conditions. METHODS: Retrospective 
secondary database analysis using Medical Expenditure Panel Survey data from years 
2000–2003 was conducted. Patients identiﬁed using the 3-digit ICD-9 codes: diabe-
tes(250) depression(311) and anxiety(300). QOL was measured using EQ-5D & pro-
ductivity measured using absenteeism data. RESULTS: A total of 12,858 patients were 
identiﬁed, 11% of patients had two or more of the conditions studied. About 17% 
of diabetes patients had an EQ-5D index score of 0.30, compared to 20% each on 
depression and anxiety. All 3 conditions had signiﬁcant impact on patient’s overall 
QOL (p  0.001). Mean EQ 5D index for diabetes was 0.65 (95% CI 0.64–0.66), 
depression—0.62 (95% CI 0.61–0.63), and anxiety—0.62 (95% CI 0.61–0.64). More 
number of patients with depression and anxiety missed work (21%) and stayed in bed 
(17%) due to illness compared to diabetes patients (12% and 9% respectively), but 
the mean days diabetes patients missed work was higher—12.15 (95% CI 10.38–
13.92) compared to anxiety—9.39 (95% CI 7.8–10.89) and depression—8.88 (95% 
CI 7.79–9.96) CONCLUSIONS: All three conditions were found to have a signiﬁcant 
negative impact on patient’s QoL and productivity. Our research indicates that anxiety 
and depression inﬂict similar disease burden compared to diabetes on patient. Future 
research should focus on reducing this burden.
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OBJECTIVES: To understand how insulin is initiated, describe patients with type 2 
diabetes (T2DM) initiating insulin in UK primary care, and look at changes in therapy, 
clinical outcomes and contact with health care professionals (HCPs) after insulin ini-
tiation. METHODS: Patients aged q18 years with a code for T2DM initiating insulin 
(baseline) from May 2004 to May 2006 were identiﬁed in the THIN database. Patient 
characteristics, clinical measures, treatment and contact with HCPs were collected at 
baseline and during 6 months follow-up. RESULTS: A total of 4045 patients met the 
inclusion criteria, 56% were male. Patient characteristics at baseline [mean (SD)] were; 
age: 62.6(13.3) years, BMI: 30.2(6.5) kg/m2 and HbA1c: 9.6%(2.0%). The most preva-
lent co-morbidities were hypertension (63%), coronary heart disease (26%), hyperli-
paedemia (24%), and depression (22%). 97.4% of patients had contact with their 
GP-surgery in the 6 months before insulin initiation, mean 7.1 contacts; 78.1% were 
referred to secondary care; and 18% were hospitalised. In the 12 months prior to 
insulin initiation 8.5% of patients had no prescriptions for oral antidiabetic medica-
tions (OAD), 13.4% for a single OAD class and 78.1% for q2 different OAD classes. 
52.4% of patients initiated intermediate/long acting insulin therapy only, a further 
41.6% pre-mix insulin only and the remainder initiated basal bolus (4.0%) or fast 
acting only (2.1%). During follow-up, 14.7% discontinued insulin therapy, 6.8% 
switched to a different regimen and 4.7% intensiﬁed therapy; adding mealtime insulin. 
Of the patients with a measurement during follow-up (n  3024), 17.3% achieved 
target HbA1c (7%). Clinical outcomes during follow-up [mean (SD)] were; HbA1c: 
8.3 (1.6)% and BMI: 30.7 (6.6) kg/m2. There was a slight increase in contact with 
HCPs during follow-up, mean 8.5 GP-surgery contacts. CONCLUSIONS: Patients 
had elevated HbA1c at insulin initiation, simple regimens were favoured; during a 
6 month follow-up a high proportion of patients failed to achieve glycaemic target.
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OBJECTIVES: To examine economic, clinical, and humanistic outcomes of a pharma-
cist-provided Medication Therapy Management (MTM) program. METHODS: One 
year prospective, pre-post longitudinal study. Employees and dependents with a diag-
nosis of Type 2 diabetes were included. Pharmacists provided MTM services at 7 com-
munity pharmacies on ﬁve occasions in one year. Data collected: economic outcomes 
included costs and numbers of ER visits hospitalizations etc., clinical (A1C, blood 
pressure etc.), social (caffeine intake, alcohol consumption etc.), and process measures 
(podiatrist visits, eye exams, etc.), humanistic (patient’s quality of life (SF-36), medica-
tion adherence etc.). Data was analyzed using SPSS v. 16.0. Descriptive statistics, Wil-
coxon signed-rank tests and Friedman tests were used. Data analyses for the period 
between baseline and 6 month is given below. RESULTS: Ninety ﬁve patients enrolled 
at baseline. Mean A1c improved from 8.02 to 7.67 (p  0.20). Patients with uncon-
trolled A1cs at baseline saw a signiﬁcant decrease toward goal at six months. (p  0.01). 
Systolic blood pressure improved from 136.00 to 131.94 mmHg (p  0.221) and 
improved signiﬁcantly for patients with baseline SBP q 140 (p  0.000). Patients satis-
faction (p  0.000) and adherence improved from baseline (p  0.015). Quality of life 
scores improved but these changes were not signiﬁcant. Visits to specialty physicians 
improved signiﬁcantly from the previous year. On average, physician ofﬁce visits 
reduced from 10.2 to 8.36. Number and costs for ER visits decreased. Average hospi-
talization costs decreased from $ 22,252.24 to $ 17,016.19 and length of stay decreased 
by approximately 1.4 days. Total costs decreased by 62.69% (^$200,000). CONCLU-
SIONS: This MTM program has demonstrated improved outcomes and cost savings 
within the ﬁrst six months. Final results for the one year time point will be presented.
PDB60
EVALUATION OF THE PATIENT’S PERSPECTIVE OF MEDICAL CARE IN 
TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS
Stark R1, Holle R2, Schunk M3, Meisinger C3, Leidl R4
1Helmholtz Zentrum München, Neuherberg , Germany, 2Helmholtz Zentrum München, 
Neuherberg, Germany, 3Helmholtz Zentrum München, Neuherberg, Germany, 4Helmholtz 
Zentrum München—German Research Center for Environmental Health, Neuherberg (by 
Munich), Germany
OBJECTIVES: Diabetes disease management programmes (DDMP) were introduced 
in German statutory health insurance companies to improve medical care by funding 
health care based on evidence-based medical guidelines. The aim of this study was to 
compare persons with type 2 diabetes (DM2s) enrolled in a DDMP to those not 
enrolled regarding quality of health care and medical endpoints. METHODS: A popu-
lation based follow-up study was performed by the Cooperative Health Research in 
the Region of Augsburg (KORA) between 2006 and 2008. All DM2s received a 
